GET DAILY SIGNALSAIM ImmunoTech (AIM): A Clinical-Stage Biotech Centered on Ampligen for Pancreatic Cancer
Key Takeaways
- AIM is the NYSE American ticker for AIM ImmunoTech Inc., a clinical-stage immuno-pharma company headquartered in Ocala, Florida.
- The company's lead product candidate, Ampligen (rintatolimod), is being developed primarily for late-stage pancreatic cancer and is not yet approved by the U.S. Food and Drug Administration (FDA).
- AIM ImmunoTech traces its roots to 1966 and was formerly known as Hemispherx Biopharma, Inc. before rebranding in 2019.
- The company generates minimal commercial revenue and has reported ongoing net losses, a profile typical of early-stage biotechnology firms funded through capital raises.
- Investor attention centers on clinical trial progress, particularly the DURIPANC study combining Ampligen with an immunotherapy drug for metastatic pancreatic cancer.
Company Overview
AIM ImmunoTech Inc. is a small-cap biotechnology company focused on researching and developing therapies for cancers, viral diseases, and immune-deficiency disorders. Investors follow AIM because its clinical pipeline centers on a single platform molecule, Ampligen, which the company sees as a way to address significant unmet medical needs in oncology and antiviral treatment. From what I see, understanding this company requires recognizing that, like many development-stage biotechs, its value is tied to clinical trial outcomes rather than current sales. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business and Product Profile
AIM ImmunoTech is an immuno-pharma company that develops therapeutics intended to enhance the body's natural immune and antiviral defenses. The company was founded in 1966 and is headquartered in Ocala, Florida, with its shares listed on the NYSE American exchange. It was previously named Hemispherx Biopharma, Inc. and adopted the AIM ImmunoTech name in August 2019.
The company's core products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA molecule that acts as a selective TLR3 agonist and is the company's lead development asset. Alferon N Injection is a natural-source alpha interferon product.
Ampligen has not been approved or marketed in the United States by the FDA, though it has been approved for commercial sale in Argentina for the treatment of severe Chronic Fatigue Syndrome (CFS). AIM ImmunoTech's primary strategic focus is developing Ampligen for the treatment of late-stage pancreatic cancer, a disease with substantial unmet medical need. The company is also exploring Ampligen across other solid tumors, antiviral applications, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), post-COVID conditions, and as a vaccine adjuvant.
In terms of business model, AIM ImmunoTech is a development-stage enterprise rather than a commercial pharmaceutical company. Its operations revolve around clinical trials, regulatory filings, and intellectual property, and it has historically generated only minimal product revenue. The company's financial profile reflects this: it reports very small revenue figures alongside significant research and development expenses and recurring net losses, funded largely through equity and warrant offerings. The company maintains a patent portfolio, including combination-therapy patents in the United States, Japan, and Europe, as well as orphan drug designations for Ampligen in the U.S. and European Union.
The company's market position is that of a niche clinical-stage biotech competing within the broader oncology and immunotherapy landscape, where much larger pharmaceutical and biotechnology companies operate. Its competitive positioning rests on Ampligen's differentiated mechanism of action and the possibility of combination use with checkpoint inhibitors.
What Draws Investors to AIM
Investor interest in AIM is driven primarily by the potential of its Ampligen clinical program. The most closely watched effort is the Phase 2 DURIPANC study, an investigator-initiated trial conducted with the Erasmus MC Cancer Institute that evaluates Ampligen in combination with AstraZeneca's anti-PD-L1 checkpoint inhibitor Imfinzi (durvalumab) in patients with metastatic pancreatic cancer whose disease is stable after standard chemotherapy.
Pancreatic cancer is widely regarded as a difficult-to-treat malignancy with limited effective options, so positive clinical data could carry meaningful value for the company. Beyond oncology, Ampligen's broad-spectrum antiviral research and its potential role in addressing post-COVID conditions give the company multiple avenues for development, which some investors view as optionality. The company's orphan drug designations and patent protections are also strategic assets that could support market exclusivity if Ampligen advances toward approval. One thing that stands out is how these factors could influence long-term outcomes.
Key Risks to Consider
Investing in AIM carries substantial risk, consistent with clinical-stage biotechnology. The company's lead product has not received FDA approval, and drug development is inherently uncertain; clinical trials can fail or be delayed. AIM ImmunoTech generates minimal revenue and has reported persistent operating losses, meaning it relies on external financing, including equity sales and warrant exercises, which can dilute existing shareholders.
Additional risks include intense competition from larger, better-funded pharmaceutical and biotechnology companies, regulatory hurdles across multiple jurisdictions, manufacturing and supply limitations, and the possibility that Ampligen may not demonstrate sufficient safety or efficacy in later-stage trials. The company has also faced listing-compliance matters with the NYSE American, underscoring the financial and operational challenges common to small biotech firms. Investors should understand that the company's market position remains unproven until clinical milestones are achieved.
Exploring Market Ideas with Tickeron’s AI Screener
In my own research process, I frequently use Tickeron’s AI Screener to screen for ideas across sectors and compare small-cap names like AIM against peers based on technicals, fundamentals, and AI signals. It provides a structured way to filter opportunities that match specific strategies without replacing deeper due diligence on clinical developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AIM's RSI Oscillator ascending out of oversold territory
The RSI Indicator for AIM moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 36 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for AIM just turned positive on October 15, 2026. Looking at past instances where AIM's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +6.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where AIM advanced for three days, in 159 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
AIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AIM as a result. In 100 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AIM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.784) is normal, around the industry mean (3.482). P/E Ratio (-0.219) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.859) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. AIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders
Industry Biotechnology
Advertisement